Transcription factors Brn-3α and TRIM16 in cancers, association with hormone reception.

Brn-3α Cancer research Cancers Steroid receptors TRIM16

Journal

Heliyon
ISSN: 2405-8440
Titre abrégé: Heliyon
Pays: England
ID NLM: 101672560

Informations de publication

Date de publication:
Aug 2019
Historique:
received: 26 02 2019
revised: 01 07 2019
accepted: 11 07 2019
entrez: 30 8 2019
pubmed: 30 8 2019
medline: 30 8 2019
Statut: epublish

Résumé

Sex hormones, regulating normal physiological processes of most tissues and organs, are considered to be one of the key factors in the development of hormone-dependent cancer and formation of the hormone-resistant tumor phenotype. Recently, the importance of the system for control of hormone receptors expression mediated by nuclear peptides became evident. This system is involved in the regulation of normal physiological processes, in the pathogenesis of many diseases as well as oncogenesis. In the review, we discuss the relationships of the two regulatory peptides - Brn-3α, TRIM16 with hormone receptors. The transcription factor Brn-3α is able to affect the transcription activity of androgen and estrogen receptors. It is observed the participation of TRIM16 protein in the pathogenesis of hormone-dependent tumors due to its "anti-estrogenic effect". Additionally, they are involved in the key intracellular processes, such as proliferation, cell differentiation, and programmed death - apoptosis. Thus, Brn-3α and TRIM16 are associated with cancer development and progression. By understanding these alterations, we can identify potential markers and novel biochemical therapeutic targets. It makes clear the association between classical hormone-dependent tumors and less sensitive ones with the modification in the level of hormone receptors.

Identifiants

pubmed: 31463379
doi: 10.1016/j.heliyon.2019.e02090
pii: S2405-8440(19)35750-0
pii: e02090
pmc: PMC6708992
doi:

Types de publication

Journal Article Review

Langues

eng

Pagination

e02090

Références

J Biol Chem. 1999 Oct 1;274(40):28521-7
pubmed: 10497216
Int J Biochem Cell Biol. 2001 Oct;33(10):1027-39
pubmed: 11470235
Oncogene. 2001 Aug 9;20(35):4899-903
pubmed: 11521202
Nucleic Acids Res. 2001 Nov 15;29(22):4530-40
pubmed: 11713302
Oncogene. 2002 Sep 5;21(39):6123-31
pubmed: 12203124
Mol Biotechnol. 2002 Oct;22(2):123-7
pubmed: 12405260
Cancer Biol Ther. 2002 Jul-Aug;1(4):428-32
pubmed: 12432261
Nucleic Acids Res. 2002 Nov 15;30(22):4872-80
pubmed: 12433990
J Biol Chem. 2005 Mar 25;280(12):11851-8
pubmed: 15598651
Oncogene. 2006 Jan 5;25(1):51-60
pubmed: 16247485
Prostate Cancer Prostatic Dis. 2006;9(1):83-91
pubmed: 16276351
J Biol Chem. 2006 Jun 30;281(26):18246-56
pubmed: 16636064
Cell. 2006 Nov 3;127(3):469-80
pubmed: 17081971
Nat Rev Immunol. 2008 Nov;8(11):849-60
pubmed: 18836477
Cancer Lett. 2009 May 8;277(1):82-90
pubmed: 19147277
J Biol Chem. 2010 May 14;285(20):15286-95
pubmed: 20228055
J Ovarian Res. 2010 Jul 29;3:17
pubmed: 20670407
Oncogene. 2010 Nov 18;29(46):6172-83
pubmed: 20729920
Bull Exp Biol Med. 2010 Jul;149(1):82-5
pubmed: 21113465
Biochim Biophys Acta. 2011 Nov;1813(11):1938-45
pubmed: 21708191
J Pathol. 2012 Feb;226(3):451-62
pubmed: 22009481
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2011 Jul;27(7):801-2
pubmed: 22031962
PLoS One. 2012;7(5):e37470
pubmed: 22629402
Apoptosis. 2013 May;18(5):639-51
pubmed: 23404198
EMBO Mol Med. 2013 Jun;5(6):919-34
pubmed: 23666755
Carcinogenesis. 2014 Sep;35(9):2142-53
pubmed: 24986896
Folia Biol (Praha). 2014;60(3):144-51
pubmed: 25056437
Oncotarget. 2014 Oct 30;5(20):10127-39
pubmed: 25333256
Mol Biol (Mosk). 2014 May-Jun;48(3):444-51
pubmed: 25831894
Biochem Biophys Res Commun. 2015 May 15;460(4):1021-8
pubmed: 25843803
PLoS One. 2015 Jun 09;10(6):e0128705
pubmed: 26057869
Trends Endocrinol Metab. 2015 Sep;26(9):477-85
pubmed: 26242817
Oncol Rep. 2016 Feb;35(2):1204-12
pubmed: 26718507
Int J Oncol. 2016 Apr;48(4):1639-49
pubmed: 26892350
Cancer Lett. 2016 May 1;374(2):315-23
pubmed: 26902425
Oncotarget. 2016 Aug 9;7(32):52166-52178
pubmed: 27447557
J Biol Chem. 2016 Jul 22;291(30):15909
pubmed: 27451431
Dev Cell. 2016 Oct 10;39(1):13-27
pubmed: 27693506
Oncol Res. 2017 Apr 14;25(4):551-558
pubmed: 27737724
Int J Mol Med. 2016 Dec;38(6):1734-1742
pubmed: 27748839
J Clin Endocrinol Metab. 1997 Jan;82(1):89-94
pubmed: 8989239
Mol Cell Biol. 1998 Feb;18(2):1029-41
pubmed: 9448000
Dev Biol. 1998 May 15;197(2):155-69
pubmed: 9630743
Int J Biochem Cell Biol. 1998 Nov;30(11):1153-7
pubmed: 9839440

Auteurs

Liudmila V Spirina (LV)

Laboratory of Tumor Biochemistry, Cancer Research Institute, Tomsk National Research Medical Center of the Russian Academy of Sciences, 5 Koopertivny Street, Tomsk, 634050, Russia.
Division of Biochemistry and Molecular Biology, Siberian State Medical University, 2, Moskovsky trakt, Tomsk, 634050, Russia.

Natalia V Yunusova (NV)

Laboratory of Tumor Biochemistry, Cancer Research Institute, Tomsk National Research Medical Center of the Russian Academy of Sciences, 5 Koopertivny Street, Tomsk, 634050, Russia.
Division of Biochemistry and Molecular Biology, Siberian State Medical University, 2, Moskovsky trakt, Tomsk, 634050, Russia.

Irina V Kondakova (IV)

Laboratory of Tumor Biochemistry, Cancer Research Institute, Tomsk National Research Medical Center of the Russian Academy of Sciences, 5 Koopertivny Street, Tomsk, 634050, Russia.

Natalia V Tarasenko (NV)

Division of Medical Genetics, Siberian State Medical University, 2, Moskovsky trakt, Tomsk, 634050, Russia.
Laboratory of Population Genetics, Institute of Medical Genetics, Tomsk National Research Medical Center of the Russian Academy of Sciences, 5 Koopertivny Street, Tomsk, 634050, Russia.

Classifications MeSH